5:54 PM
 | 
Nov 08, 2013
 |  BC Extra  |  Company News

Corcept submits mifepristone MAA

Corcept Therapeutics Inc. (NASDAQ:CORT) disclosed in its 3Q13 financial results that it submitted an MAA to EMA for Corluxin mifepristone to treat endogenous Cushing's syndrome. Corcept...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >